- Home
- HLVX vs ATYR Comparison
HLVX vs ATYR Comparison
Compare HLVX & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HLVX
- ATYR
- Stock Information
- Founded
- HLVX 2020
- ATYR 2005
- Country
- HLVX United States
- ATYR United States
- Employees
- HLVX N/A
- ATYR N/A
- Industry
- HLVX Biotechnology: Pharmaceutical Preparations
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HLVX Health Care
- ATYR Health Care
- Exchange
- HLVX Nasdaq
- ATYR Nasdaq
- Market Cap
- HLVX 104.3M
- ATYR 105.8M
- IPO Year
- HLVX 2022
- ATYR 2015
- Fundamental
- Price
- HLVX $2.09
- ATYR $1.05
- Analyst Decision
- HLVX Hold
- ATYR Buy
- Analyst Count
- HLVX 1
- ATYR 6
- Target Price
- HLVX $2.00
- ATYR $8.88
- AVG Volume (30 Days)
- HLVX 862.9K
- ATYR 16.3M
- Earning Date
- HLVX 11-06-2025
- ATYR 11-06-2025
- Dividend Yield
- HLVX N/A
- ATYR N/A
- EPS Growth
- HLVX N/A
- ATYR N/A
- EPS
- HLVX N/A
- ATYR N/A
- Revenue
- HLVX N/A
- ATYR N/A
- Revenue This Year
- HLVX N/A
- ATYR $420.85
- Revenue Next Year
- HLVX N/A
- ATYR $1,919.44
- P/E Ratio
- HLVX N/A
- ATYR N/A
- Revenue Growth
- HLVX N/A
- ATYR N/A
- 52 Week Low
- HLVX $1.34
- ATYR $0.97
- 52 Week High
- HLVX $2.17
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- HLVX 51.29
- ATYR 22.56
- Support Level
- HLVX $2.07
- ATYR $0.97
- Resistance Level
- HLVX $2.11
- ATYR $6.50
- Average True Range (ATR)
- HLVX 0.02
- ATYR 0.45
- MACD
- HLVX -0.00
- ATYR -0.53
- Stochastic Oscillator
- HLVX 50.00
- ATYR 1.46
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.